News and Trends 8 Jul 2015
CureVac’s mRNA Therapy is Working Against Prostate Cancer
mRNA based immunotherapies are no pipe dream anymore. Germany’s CureVac just presented encouraging results of its Phase IIa clinical study. The firm’s lead mRNA candidate CV9103 is well tolerated and immunogenic in patients with prostate cancer. Based on the favorable data, CureVac initiated a Phase IIb study with a follower prostate cancer vaccine. Just recently, […]